Uterine teratoma and the role of short-tandem repeat genotyping in understanding origins Authors: Abdelrahman AlAshqar, Vijaya Kadam Maruthi, Rita Abi-Raad, Michelle Greenman, Pei Hui, Elena Ratner, Gary Altwerger, Alessandro Santin, Vaagn Andikyan Published: 2024 ABSTRACT Highlights:•Uterine teratomas are a rare entity with a debated origin but some theories have been proposed to explain their pathogenesis.•Recently introduced molecular testing, including short-tandem repeat genotyping, has revolutionized our understanding of these rare tumors.•Studies should investigate the properties and tumorigenic potential of uterine pluripotent stem cells to understand uterine teratoma origins. Introduction Teratomas represent the most common germ cell tumor and are predominately gonadal in origin, with those arising from the ovary comprising 95% of all teratomas (Desita and Mardiyana, 2023). Although a rare occurrence, teratomas can develop extragonadally, primarily in the midline along the migration path of germ cells (O'Donovan et al., 2014). Uterine teratomas, especially those arising within the uterine corpus, are exceptionally uncommon and their occurrence has been described in only a handful of case reports (Ben Ameur El Youbi et al., 2013, Wang et al., 2011, Chou et al., 2022, Lin et al., 2020). Among symptomatic women, the common presentation includes abnormal uterine bleeding and pelvic pain typically in the second to fourth decades of life, although incidences in young girls and postmenopausal women have also been reported (Ben Ameur El Youbi et al., 2013, Zhao et al., 2021). The origin of uterine teratomas has been debated and is more ambiguous compared to its ovarian counterpart. While abnormal passage of primordial germ cells along midline structures has classically been believed to be the inciting event, other theories have also been discussed, including the blastomere and pluripotent stem cell theories (Zhao et al., 2021). The blastomere theory states that the teratoma develops during the process of fertilization and implants at any part of the maternal reproductive tract, typically in the cervix or endometrium, and eventually grows in a tumorigenic fashion from remnant pluripotent embryonic cells following a missed abortion or a nondelivered papyraceous twin (Stolnicu et al., 2017, Linder et al., 1975). Alternatively, fetal tissue can be accidentally inoculated into the uterine wall during instrumentation such as curettage procedures (Newsom-Davis et al., 2009, Siddon and Hui, 2010). The parthenogenetic theory, on the other hand, proposes that the teratoma develops from misplaced primordial germ cells during embryogenesis that would otherwise normally migrate from the fetal yolk sac endoderm along the midline then laterally to the gonadal ridge, where they differentiate into diploid oogonia and arrest in the prophase of meiosis I until ovulation ensues at puberty (Wang et al., 2011, Zhao et al., 2021). In this case report, we present a perplexing case of uterine teratoma treated surgically and ultimately confirmed using short-tandem repeat (STR) genotyping. Case description A 44-year-old primiparous woman presented with a four-week history of light vaginal bleeding. Of note, she had previously undergone endometrial ablation four years prior for heavy menstrual bleeding and had successfully achieved amenorrhea until her current presentation. Abdominal and pelvic examinations were unremarkable. The uterus was a normal size, and no adnexal masses were palpable. Transvaginal ultrasonography showed a cystic lesion near the cervix and an endometrial thickness of 1 cm. An endometrial biopsy was performed and showed fragments of benign mature adipose tissue and scant benign smooth muscles and keratin debris. No evidence of malignancy or myometrial invasion was identified; however, significant sampling limitations were present due to history of endometrial ablation. The patient was counseled on the possible differential diagnoses, including uterine lipoma, lipoleiomyoma, uterine teratoma, and uterine perforation as a complication of biopsy. Magnetic resonance imaging (MRI) of the pelvic was performed to better delineate the pathology given limited visualization of the mass on ultrasound and help inform treatment planning. MRI of the pelvis showed a complex, cystic, fat containing mass in the lower uterine segment measuring 2.0 × 3.5 × 2.3 cm (Fig. 1). No evidence of adjacent infiltration or lymphadenopathy was appreciated.Fig. 1Pelvic MRI showing a complex, cystic, fat containing mass in the lower uterine segment measuring 2.0 × 3.5 × 2.3 cm. Pelvic MRI showing a complex, cystic, fat containing mass in the lower uterine segment measuring 2.0 × 3.5 × 2.3 cm. The constellation of findings was discussed with the patient, with an emphasis on the unusual presence of adipose tissue inside the uterus. Management options, including ongoing observation or surgical treatment with either a hysteroscopy or hysterectomy, were heavily discussed. She ultimately opted for a total hysterectomy, opportunistic bilateral salpingectomy, and additional staging as indicated by intraoperative findings. The patient underwent an uncomplicated robot-assisted total laparoscopic hysterectomy and bilateral salpingectomy. Intraoperative findings were notable for normal appearing adnexa and uterus without exophytic or subserosal lesions. No evidence of ascites, gross lymphadenopathy, or carcinomatosis was noted. Intraoperative frozen section of the uterus was notable for uterine teratoma and no histologic features of malignancy. Decision was therefore made to preserve the ovaries. She had an uneventful postoperative recovery, with complete resolution of her bleeding. Final pathology confirmed the presence of a 3.5-cm mature uterine teratoma arising from the posterior lower uterine segment. Grossly, the mass was described as pedunculated and tan yellow in color (Fig. 2). Microscopic examination showed mature tissue derived from all three germ cell layers. Ectodermal (skin with adnexal structures), mesodermal (mature adipose tissue, bone, cartilage, bone marrow, and smooth muscle) and endodermal (gastrointestinal epithelium and salivary tissue) elements were identified (Fig. 3). No myometrial invasion or immature components suggestive of malignancy were noted.Fig. 2Gross specimen showed a 3.5 × 2.5 × 1.5 cm tan-yellow, pedunculated solid mass within the posterior lower uterine segment, located 3.4 cm from the squamocolumnar junction. The mass has solid and fatty lobulated cut surfaces with foci of bone and cartilage. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 3Microscopic examination showed a mass within the endometrium consisting of mature tissue derived from all three germ cell layers. Panel A: adipose tissue, cartilage, and salivary tissue. Panel B: smooth muscle and glandular epithelium. Panel C: Skin and subcutaneous adipose tissue. Panel D: bone marrow. Gross specimen showed a 3.5 × 2.5 × 1.5 cm tan-yellow, pedunculated solid mass within the posterior lower uterine segment, located 3.4 cm from the squamocolumnar junction. The mass has solid and fatty lobulated cut surfaces with foci of bone and cartilage. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) Microscopic examination showed a mass within the endometrium consisting of mature tissue derived from all three germ cell layers. Panel A: adipose tissue, cartilage, and salivary tissue. Panel B: smooth muscle and glandular epithelium. Panel C: Skin and subcutaneous adipose tissue. Panel D: bone marrow. To confirm the teratoma diagnosis, comparative STR genotyping was performed on the teratoma and normal fallopian tube tissue using formalin-fixed paraffin-embedded tissue samples. A paraffin block containing both tumor and fallopian tube tissue was selected, and 10 unstained sections were created. Target tissue areas were scraped separately from the unstained sections into a microcentrifuge tube. DNA was extracted by hydrothermal pressure method of simultaneous deparaffinization and lysis of formalin-fixed paraffin-embedded tissue, followed by conventional column purification to obtain high-quality DNA. Tissue genotyping using PowerPlex® 16 System (Promega Corporation, Madison, WI, USA) was performed by multiplex polymerase chain reaction (PCR) at 15 short-tandem repeat loci according to manufacturer instructions. One µL of the PCR product was mixed with 13 µL of Hi-Di and 0.5 µL sizing marker (GeneScan-500LIZ, Applied Biosystems, Inc.), followed by capillary electrophoresis on an ABI3130 platform. Data collection and analysis were performed using GeneMapper version 3.7 (Applied Biosystems, Inc., Foster City, California, USA). STR allelic patterns were identified by fluorescent color and the expected size range of the PCR products. Matching allelic patterns at each STR locus were present between the teratoma and fallopian tube tissue except for loss of heterozygosity in six of 16 STR loci, supporting a teratoma diagnosis. Results of the STR genotyping are shown in Fig. 4.Fig. 4A comparative Short-Tandem Repeat (STR) genotyping was performed on normal fallopian tube tissue and the teratoma. Matching allelic patterns at each STR locus are present apart from loss of heterozygosity in six of 16 STR loci. A comparative Short-Tandem Repeat (STR) genotyping was performed on normal fallopian tube tissue and the teratoma. Matching allelic patterns at each STR locus are present apart from loss of heterozygosity in six of 16 STR loci. Discussion We present a case of uterine teratoma treated surgically and confirmed histologically and with STR genotyping. The origins of uterine teratoma have been heavily debated in the literature and shown to be likely discrepant from those of the ovarian counterpart. While ovarian teratomas are believed to parthenogenetically originate from ovarian oocytes that stalled during embryonic migration (Snir et al., 2020), the origin of uterine teratomas can be described by two main hypotheses, the blastomere theory and the parthenogenetic theory described above (Lin et al., 2020). The blastomere theory has been occasionally refuted in the literature, at least for ovarian teratomas, given their typical 46, XX karyotype and large genetic resemblance to the maternal host (Newsom-Davis et al., 2009, Sait and Simpson, 2004). In addition, our patient had her child many years ago and underwent endometrial ablation four years prior to her current presentation. Establishing causality if her prior ablation procedure contributed to the teratoma development is impossible; however, theoretically, the radiofrequency energy from ablation would promote cellular necrosis rather than tumorigenesis, rendering the blastomere theory in this context highly unlikely. In addition, the genetic similarity between the teratoma and host tissue (fallopian tube) and absence of unique paternal allele(s) by STR genotyping definitively rule out this possibility in our case. On the other hand, uterine teratomas abiding by the parthenogenetic theory have a predilection to arise in the midline structures as observed in our case due to failure of primordial germ cell migration (Zhao et al., 2021). This theory has been largely favored to describe the origins of ovarian teratomas and can be extrapolated to provide plausible explanations of the origins of its uterine counterpart (Linder et al., 1975). According to this theory, teratomas can arise from primordial germ cells at various stages of gametogenesis yielding distinct genetic and molecular makeups (Linder et al., 1975). In the first scenario, a single mature ovum that has completed the first and second meiotic divisions can duplicate its chromosomes and proliferate forming a teratoma, which in such case, would be homozygous for all chromosomes and genetic markers (Linder et al., 1975). In the second scenario, two mature ova can fuse or autofertilize to form a teratoma with homozygous and heterozygous components (Linder et al., 1975). In the third scenario, teratomas arising from an ovum with a suppressed first meiotic division are frequently heterozygous with a similar genetic makeup to the host (Linder et al., 1975). Lastly, teratomas can develop prior to the second meiotic division, wherein homozygosity and heterozygosity can be seen though in proportion to the number and nature of crossover events, whereas homozygosity will be maintained near the centromeres where crossover is unlikely to happen (Linder et al., 1975). When extrapolating to our case, the presence of heterozygous loci in our patient’s teratoma suggests that the tumorigenic process may have started before the completion of meiosis I, i.e. when the primordial germ cell had the full chromosomal complement (diploid), explaining the genetic heterozygosity. Using a similar technique to ours, Wang et al. conducted a comparative analysis of DNA profiles on normal uterine tissue and uterine teratomas using STR genotyping and, on the contrary, concluded that uterine teratomas do not develop from the classic parthenogenetic process and rather originate from pluripotential uterine stem cells or as we likewise proposed, from primordial germ cells before completion of meiosis I (Wang et al., 2011). In an intriguing experiment by Gutierrez-Aranda et al., mice injected with human-induced pluripotent cells developed teratomas more efficiently and faster than those injected with embryonic stem cells regardless of injection site and without differences in teratoma composition (Gutierrez-Aranda et al., 2010). While unclear if uterine pluripotent stem cells manifest similar behavior, these findings provide considerable insight into the potential role of these cells in teratoma development at large, and perhaps in uterine teratomas specifically. Indeed, the genetic similarity between the uterine teratoma in our case and fallopian tube tissue may suggest a common progenitor or pluripotential cell as the culprit origin, with the non-identical loci possibly attributed to mutations inherent to the tumorigenic process, such as gene suppression or activation (Linder et al., 1975). Malignant transformation of benign uterine teratoma is extremely rare (occurs in only 0.5 % of all teratomas) but has been reported in the literature. Molecular analysis has revolutionized our understanding of ovarian teratoma development, and recent efforts are attempting to utilize this technique for better identification of extragonadal teratoma origins, including those arising in the uterus (Wang et al., 2011, Linder et al., 1975). Molecular results from our and prior case reports suggest that uterine teratomas may arise from pluripotent uterine stem cells or arrested germ cells at an early stage of maturation as opposed to the later stages seen in adult ovarian teratomas (Wang et al., 2011, Zhao et al., 2021, Snir et al., 2020). This is further supported by the findings of Snir et al., wherein the predominant genetic heterozygosity in prepubertal (type I) teratomas, both gonadal and extragonadal, is explained by their origin from germ cells before the completion of meiosis I (Snir et al., 2020). While this case report provides valuable insights into the pathogenic origins of uterine teratomas, STR genotyping is not devoid of limitations and only detects a certain set of polymorphic loci utilizing techniques such as single nucleotide polymorphism array. Next-generation sequencing technology will likely be promising in delineating the genetic origins of uterine teratomas (Snir et al., 2020). Additional studies should also investigate the properties, distribution, and tumorigenic potential of pluripotent stem cells in the uterus in efforts to better understand uterine teratomas and help inform therapeutic targets. Conflict of interest Alessandro Santin reports receiving research grants from IMMUOMEDICS, MERCK, BOEHINGER-INGELHEIM, GENENTECH, and TESARO, with payments being made to the institution. He also reports receiving personal consulting fees from EISAI, R-PHARM US, MERCK, and Daiichi-Sankyo. He also reports participating on a data safety monitoring or advisory board for Merck, Daiichi-Sankyo, and Gilead Science Inc. Remainder of authors have no conflict of interest to declare. Authors’ contribution Abdelrahman AlAshqar has written the manuscript. Vijaya Kadam-Maruthi, Rita Ab-Raad, and Pei Hui have performed the pathological examination and STR genotyping. Michelle Greenman, Elena Ratner, Gary Altwerger, Alessandro Santin, and Vaagn Andikyan have participated in drafting the manuscript. All authors reviewed and approved the final version of the manuscript. Consent statement Written informed consent was obtained from the patient for publication of this case report and accompanying images. CRediT authorship contribution statement Abdelrahman AlAshqar: Writing – review & editing, Writing – original draft, Data curation, Conceptualization. Vijaya Kadam-Maruthi: Writing – review & editing, Data curation. Rita Abi-Raad: Writing – review & editing, Data curation. Michelle Greenman: Writing – review & editing. Pei Hui: Writing – review & editing, Data curation. Elena Ratner: Writing – review & editing. Gary Altwerger: Writing – review & editing. Alessandro Santin: Writing – review & editing. Vaagn Andikyan: Writing – review & editing, Conceptualization.